| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.7326/0003-4819-134-5-200103060-00009 |
| P698 | PubMed publication ID | 11242497 |
| P2093 | author name string | ACE Inhibitors in Diabetic Nephropathy Trialist Group | |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type-1 diabetes | Q124407 |
| meta-analysis | Q815382 | ||
| patient | Q181600 | ||
| P304 | page(s) | 370-379 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data | |
| P478 | volume | 134 |
| Q56970799 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension |
| Q34063604 | A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 |
| Q63865921 | A new strategy for vascular complications in young people with type 1 diabetes mellitus |
| Q35616168 | A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension |
| Q35154543 | ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients? |
| Q37012091 | ACE inhibitor and ARB medication use among Medicaid enrollees with diabetes |
| Q34566259 | ACE up the sleeve - are vascular patients medically optimized? |
| Q33519176 | Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT) |
| Q39993285 | Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes |
| Q34482656 | Angiotensin II (AT(1)) receptor antagonists, diabetes, and nephropathy: do differences between the renal and systemic circulations explain the outcomes observed with ARBs and ACE inhibitors? |
| Q35087034 | Angiotensin II and the glomerulus: focus on diabetic kidney disease |
| Q24244197 | Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease |
| Q42104057 | Angiotensin-converting enzyme inhibition curbs tyrosine nitration of mitochondrial proteins in the renal cortex during the early stage of diabetes mellitus in rats |
| Q35209071 | Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics? |
| Q34311942 | Angiotensin-converting enzyme inhibitors will help in improving stroke outcome if given immediately after stroke |
| Q52739075 | Angiotensin-converting enzyme-inhibitor therapy in adolescents with type 1 diabetes in a regional cohort: Auckland, New Zealand from 2006 to 2016. |
| Q38724392 | Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients. |
| Q35876457 | Antiproteinuric effect of RAS blockade: new mechanisms |
| Q36766087 | Arterial hypertension in diabetes mellitus: from theory to clinical practice. |
| Q36448380 | Awaking Blood Pressure Surge and Progression to Microalbuminuria in Type 2 Normotensive Diabetic Patients |
| Q36599244 | Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications |
| Q48920677 | Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria? |
| Q36855006 | Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme |
| Q87393470 | Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus |
| Q35087369 | Combating diabetic nephropathy with drug therapy |
| Q36466019 | Comprehensive approach to diabetic nephropathy |
| Q47898923 | Constructing a database of individual clinical trials for longitudinal analysis |
| Q46415469 | Cross-sectional study of care, socio-economic status and complications in young French patients with type 1 diabetes mellitus |
| Q84894413 | Determining the optimal method for proteinuria detection in chronic spinal cord injury |
| Q33686761 | Development and analyses of evaluation criteria for meta-analysis-relationship between renin-angiotensin system inhibitor and diabetes mellitus |
| Q33583012 | Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease |
| Q59220162 | Diabetic nephropathy |
| Q73511309 | Diabetic nephropathy |
| Q83839547 | Diabetic nephropathy |
| Q36973440 | Diabetic nephropathy in children and adolescents |
| Q38908409 | Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. |
| Q38150065 | Diabetic nephropathy: diagnosis and treatment |
| Q38338539 | Diabetic nephropathy: landmark clinical trials and tribulations |
| Q33850444 | Diabetic nephropathy: preventing progression |
| Q36659512 | Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history |
| Q35620727 | Diabetic renal disease: from recent studies to improved clinical practice |
| Q36195282 | Do angiotensin II antagonists provide benefits beyond blood pressure reduction? |
| Q22241786 | ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary |
| Q37418807 | Early nephropathy in type 1 diabetes: the importance of early renal function decline |
| Q37055066 | Effect of angiotensin converting enzyme inhibitor on glomerular hyperfiltration in patients with type 1 diabetes |
| Q46240705 | Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy |
| Q46341499 | Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials |
| Q79796272 | Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension |
| Q37128444 | Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial. |
| Q35905849 | Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review |
| Q36302838 | Emerging drugs for diabetic nephropathy |
| Q35602657 | Emerging drugs for renal failure |
| Q36384453 | Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. |
| Q30805378 | Evidence-based mucogingival therapy. Part 2: Ordinary and individual patient data meta-analyses of surgical treatment of recession using complete root coverage as the outcome variable |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q24657844 | Guidelines for the management of chronic kidney disease |
| Q44363829 | HRT does not improve urinary albumin excretion in postmenopausal diabetic women |
| Q34507222 | High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: the influence of HDL cholesterol |
| Q28080717 | Improvements in the Management of Diabetic Nephropathy |
| Q36834059 | Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines |
| Q37051619 | In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. |
| Q34704542 | Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002 |
| Q35491275 | Inhibition of RAS in diabetic nephropathy |
| Q59489229 | Long-term prevention of diabetic nephropathy: an audit |
| Q35641628 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence |
| Q35056727 | Losartan in diabetic nephropathy |
| Q36621422 | Lost in publication: Half of all renal practice evidence is published in non-renal journals. |
| Q37104269 | Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinine |
| Q36497767 | Managing hypertension in patients with type 2 diabetes mellitus |
| Q31016826 | Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. |
| Q35161366 | Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes |
| Q34004759 | Microalbuminuria in diabetes mellitus. |
| Q34825007 | Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy |
| Q37597493 | Microvascular and macrovascular complications associated with diabetes in children and adolescents |
| Q31031617 | Microvascular complications. Retinopathy and nephropathy |
| Q36216253 | New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics |
| Q35172470 | New horizons for stroke prevention: PROGRESS and HOPE. |
| Q38265818 | Novel effective drugs for diabetic kidney disease? or not? |
| Q35168051 | Outcome studies in diabetic nephropathy |
| Q48561405 | Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. |
| Q28193780 | Prevention and treatment of ischemic heart disease in patients with diabetes mellitus |
| Q36842087 | Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Dia |
| Q38748756 | Proteinuria causes dysfunctional autophagy in the proximal tubule |
| Q35581300 | Proteinuria in diabetic nephropathy: treatment and evolution |
| Q45285109 | Proteinuria/creatininuria index and its correlation with the 24-hour proteinuria in renal transplanted patients |
| Q46156709 | Race and kidney disease: the scope of the problem |
| Q56970710 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document |
| Q26745900 | Recent advances in managing and understanding diabetic nephropathy |
| Q36330445 | Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine |
| Q93609101 | References |
| Q80363801 | Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment : an observational study in 38 016 patients in primary care |
| Q35660808 | Renal function in the patient with hypertension |
| Q33183125 | Role of ACE inhibitors in patients with diabetes mellitus |
| Q89486489 | Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography |
| Q35904809 | Slowing the progression of adult chronic kidney disease: therapeutic advances. |
| Q30250319 | Social Determinants of Racial Disparities in CKD. |
| Q37508156 | Status and rationale of renoprotection studies in adolescents with type 1 diabetes |
| Q39165618 | Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. |
| Q34434932 | Systemic considerations in the management of diabetic retinopathy |
| Q74550166 | Targeting the renin-angiotensin system in patients with renal disease |
| Q36412693 | The Ontario printed educational message (OPEM) trial to narrow the evidence-practice gap with respect to prescribing practices of general and family physicians: a cluster randomized controlled trial, targeting the care of individuals with diabetes a |
| Q37741783 | The RAAS in the pathogenesis and treatment of diabetic nephropathy |
| Q33202419 | The business case for quality: combining medical literature research with health plan data to establish value for nonclinical managers |
| Q36178419 | The changing epidemiology of diabetic microangiopathy in type 1 diabetes. |
| Q37597463 | The delivery of ambulatory diabetes care to children and adolescents with diabetes |
| Q30311092 | The intrarenal renin-angiotensin system and diabetic nephropathy |
| Q53364785 | The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure. |
| Q37788947 | The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor |
| Q35065528 | The renin-angiotensin-aldosterone system and the eye in diabetes |
| Q34786560 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies |
| Q36421051 | The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension |
| Q30340930 | The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. |
| Q35688911 | Treatment of hypertension and microalbuminuria in children and adolescents with type 1 diabetes mellitus |
| Q40627664 | Trends in hypertension management in Type I diabetes across Europe, 1989/1990 - 1997/1999. |
| Q37600940 | Understanding heterogeneity in meta-analysis: the role of meta-regression |
| Q37721287 | When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes |
Search more.